Literature DB >> 15772951

F-18 FDG PET-CT fusion in radiotherapy treatment planning for head and neck cancer.

Mary Koshy1, Arnold C Paulino, Rebecca Howell, David Schuster, Raghuveer Halkar, Lawrence W Davis.   

Abstract

BACKGROUND: The fusion of fluoro-2-deoxy-D-glucose-positron emission tomography (FDG-PET) with CT scans has been shown to improve diagnostic accuracy and staging in non-small cell lung cancer. We report on the influence of PET-CT fusion on the management of patients with head and neck cancer.
METHODS: Thirty-six patients with intact primary head and neck cancers treated with radiation therapy (RT) received PET-CT as part of treatment planning. Workup before PET-CT included a contrast-enhanced CT scan of the head and neck and chest X-ray; patients with nasopharyngeal and paranasal sinus primary tumors also underwent MRI.
RESULTS: Changes in TNM score and American Joint Committee on Cancer stage occurred in 13 patients (36%) and five patients (14%), respectively, based on PET-CT. RT volume and dose were altered in five patients (14%) and four patients (11%), respectively. Five patients initially were seen with carcinoma of unknown primary, and PET-CT confirmed oropharyngeal primary tumors in two. PET-CT data also detected a synchronous lung cancer in one patient.
CONCLUSION: PET-CT fusion may have a significant impact on staging and determination of RT treatment volume and dose. (c) 2005 Wiley Periodicals, Inc.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15772951     DOI: 10.1002/hed.20179

Source DB:  PubMed          Journal:  Head Neck        ISSN: 1043-3074            Impact factor:   3.147


  29 in total

1.  Evaluation of the impact of addition of PET to CT and MR scanning in the staging of patients with head and neck carcinomas.

Authors:  Maky A Hafidh; Peter D Lacy; Joe P Hughes; George Duffy; Conrad V Timon
Journal:  Eur Arch Otorhinolaryngol       Date:  2006-05-25       Impact factor: 2.503

2.  Controversies: is there a role for positron-emission tomographic CT in the initial staging of head and neck squamous cell carcinoma?

Authors:  Suresh K Mukherji; Carol R Bradford
Journal:  AJNR Am J Neuroradiol       Date:  2006-02       Impact factor: 3.825

Review 3.  Multimodality image registration with software: state-of-the-art.

Authors:  Piotr J Slomka; Richard P Baum
Journal:  Eur J Nucl Med Mol Imaging       Date:  2009-03       Impact factor: 9.236

Review 4.  The role of PET/CT in the management of patients affected by head and neck tumors: a review of the literature.

Authors:  Giovanni Cammaroto; Natale Quartuccio; Alessandro Sindoni; Francesca Di Mauro; Federico Caobelli
Journal:  Eur Arch Otorhinolaryngol       Date:  2015-05-14       Impact factor: 2.503

5.  Impact of initial FDG PET/CT in the management plan of patients with locally advanced head and neck cancer.

Authors:  F Arias; V Chicata; M J García-Velloso; G Asín; M Uzcanga; C Eito; I Quilez; A Viudez; J Saenz; I Hernández; C Caicedo; M Errasti; M Barrado; F García-Bragado
Journal:  Clin Transl Oncol       Date:  2014-07-31       Impact factor: 3.405

6.  Modification of staging and treatment of head and neck cancer by FDG-PET/CT prior to radiotherapy.

Authors:  A Abramyuk; S Appold; K Zöphel; M Baumann; N Abolmaali
Journal:  Strahlenther Onkol       Date:  2013-01-19       Impact factor: 3.621

7.  Clinical Applications of FDG PET and PET/CT in Head and Neck Cancer.

Authors:  Akram Al-Ibraheem; Andreas Buck; Bernd Joachim Krause; Klemens Scheidhauer; Markus Schwaiger
Journal:  J Oncol       Date:  2009-08-20       Impact factor: 4.375

Review 8.  PET/CT in oncology: for which tumours is it the reference standard?

Authors:  Conor D Collins
Journal:  Cancer Imaging       Date:  2007-10-01       Impact factor: 3.909

9.  Recent advances in image-guided radiotherapy for head and neck carcinoma.

Authors:  Sameer K Nath; Daniel R Simpson; Brent S Rose; Ajay P Sandhu
Journal:  J Oncol       Date:  2009-07-29       Impact factor: 4.375

Review 10.  Defining the target for radiotherapy of head and neck cancer.

Authors:  S Nuyts
Journal:  Cancer Imaging       Date:  2007-10-01       Impact factor: 3.909

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.